newsfilter
← Latest News
GlobeNewswire·

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

TSHA
  • Taysha Gene Therapies, Inc. commenced an underwritten public offering of $200.0 million in common stock & pre-funded warrants.
  • Investors may elect to receive pre-funded warrants instead of common stock to purchase additional shares.
  • The offering includes a 30-day option for underwriters to purchase up to 15% more shares under the same terms.
  • Completion of the offering is subject to market conditions with no assurance on timing, size, or final terms.
  • Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, & Cantor serve as joint book-running managers.
  • Baird acts as the lead manager for the proposed offering.
  • A shelf registration statement for the securities was filed with the SEC on November 4, 2025, & became effective upon filing.
  • Securities will be sold only via a written prospectus & prospectus supplement filed with the SEC.
  • Taysha is a clinical-stage biotechnology company developing AAV-based gene therapies for severe CNS monogenic diseases.
  • The company's lead program, TSHA-102, targets Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies.